Send to

Choose Destination
Acta Derm Venereol. 2019 Jan 1;99(1):12-17. doi: 10.2340/00015555-3035.

Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.

Author information

Department of Dermatology, Institute of Hair and Cosmetic Medicine, Wonju College of Medicine, Yonsei University, 26426 Wonju, Korea.


Treatment of male androgenetic alopecia with 5α-reductase inhibitors is efficacious. However, the risk of adverse sexual effects remains controversial. This systematic review and meta-analysis investigated the risk of adverse sexual effects due to treatment of androgenetic alopecia in male patients with finasteride, 1 mg/day, or dutasteride, 0.5 mg/day. Fifteen randomized double-blinded placebo-controlled trials (4,495 subjects) were meta-analysed. Use of 5α-reductase inhibitors carried a 1.57-fold risk of sexual dysfunction (95% confidence interval (95% CI) 1.19-2.08). The relative risk was 1.66 (95% CI 1.20-2.30) for finasteride and 1.37 (95% CI 0.81-2.32) for dutasteride. Both drugs were associated with an increased risk, although the increase was not statistically significant for dutasteride. As studies into dutasteride were limited, further trials are required. It is important that physicians are aware of, and assess, the possibility of sexual dysfunction in patients treated with 5α-reductase inhibitors.


5α-reductaseinhibitor; androgeneticalopecia; dutasteride; erectiledysfunction; finasteride; sexualdysfunction

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Medical Journals
Loading ...
Support Center